Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)

Vedang Murthy,1 Indranil Mallick,2 Abhilash Gavarraju,1 Shwetabh Sinha,1 Rahul Krishnatry,1 Tejshri Telkhade,1 Arunsingh Moses,2 Sadhna Kannan,3 Gagan Prakash,4 Mahendra Pal,4 Santosh Menon,5 Palak Popat,6 Venkatesh Rangarajan,7 Archi Agarwal,7 Sheetal Kulkarni,3 Ganesh Bakshi4

ABSTRACT

Introduction There has been an interest in studying the efficacy of extreme hypofractionation in low and intermediate risk prostate cancer utilising the low alpha/beta ratio of prostate. Its role in high-risk and node-positive prostate cancer, however, is unknown. We hypothesise that a five-fraction schedule of extreme hypofractionation will be non-inferior to a moderately hypofractionated regimen over 5 weeks in efficacy and will have acceptable toxicity and quality of life while reducing the cost implications during treatment.

Methods and analysis This is an ongoing, non-inferiority, multicentre, randomised trial (NCT03561961) of two schedules for National Cancer Control Network high-risk and/or node-positive non-metastatic carcinoma of the prostate. The standard arm will be a schedule of 68 Gy/25# over 5 weeks while the test arm will be extremely hypofractionated radiotherapy with stereotactic body radiation therapy to 36.25 Gy/5# (7 to 10 days). The block randomisation will be stratified by nodal status (N0/N+), hormonal therapy (luteinizing hormone-releasing hormone therapy/orchiectomy) and centre. All patients will receive daily image-guided radiotherapy. The primary end point is 4-year biochemical failure free survival (BFFS). The power calculations assume 4-year BFFS of 80% in the moderate hypofractionation arm. With a 5% one-sided significance and 80% power, a total of 434 patients will be randomised to both arms equally (217 in each arm). The secondary end points include overall survival, prostate cancer specific survival, acute and late toxicities, quality of life and out-of-pocket expenditure.

Discussion The trial aims to establish a therapeutically efficacious and cost-efficient modality for high-risk and node-positive prostate cancer with an acceptable toxicity profile. Presently, this is the only trial evaluating and answering such a question in this cohort.

Ethics and dissemination The trial has been approved by IEC-III of Tata Memorial Centre, Mumbai.

Trial registration number Registered with CTRI/2018/05/014054 (http://ctri.nic.in) on 24 May 2018

STRENGTHS AND LIMITATIONS OF THIS STUDY

First study addressing the role of moderate hypofractionation and stereotactic body radiation therapy (SBRT) in high-risk and node-positive prostate cancer.

Use of prostate-specific membrane antigen positron emission tomography/CT for all patients at baseline for staging and risk adapted approach.

Out-of-pocket expenditure will be collected from all patients which will potentially have a huge impact on logistics and resource utilisation especially in low-middle-income country like India.

Non-inferiority margin between standard arm and test arm kept at 9%.

No published evidence for role of SBRT in node-positive prostate cancer in the literature.

INTRODUCTION

Incidence of high-risk very high-risk prostate cancer is on a rising trend across the globe.1-4 Advanced prostate cancer accounts for 15% of all diagnosed prostate cancers in developed nations whereas in low and low-middle-income countries like India the proportion of advanced disease is estimated to be as high as 84%.5 Radiotherapy in the form of external beam radiotherapy (EBRT) and/or brachytherapy forms an integral part of management of these patients. Radiobiological studies have shown that prostate cancer has a low alpha/beta ratio in the range of 0.47 to 4.14.6 This makes hypofractionated radiotherapy radiobiologically superior than conventional fractionated (treatment time 7 to 8 weeks) schedules as it leads to a considerably higher biologically equivalent dose delivery. Prospective randomised trials have...
studied the safety and efficacy of moderate hypofractionation (treatment time 4 to 6 weeks) in prostate cancer and is now considered as the standard of care in low-risk and intermediate-risk prostate cancer.7 With the benefit shown with moderate hypofractionation, there has been a growing interest in the role of extreme hypofractionation in prostate cancer.

Extreme hypofractionation (treatment duration 7 to 10 days) with stereotactic body radiation therapy (SBRT) has an emerging role as an alternative technique to deliver high-dose radiotherapy to the prostate comparable to brachytherapy, but with a non-invasive approach. However, the acute and late toxicities remain a concern with SBRT. Multiple single arm series on the use of SBRT as the primary treatment for prostate cancer have suggested the treatment to be safe but these studies have a majority of patients from low/intermediate risk group. The results of HYPO-RT-PC trial published recently supports the safety of SBRT in low-risk/intermediate-risk prostate cancer.8

The data with regards to extreme hypofractionation for high-risk prostate cancer is still sparse. Recently, the early toxicity and quality of life results of a phase I/II study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN) has demonstrated the safety of SBRT for these patients.9 Similarly, a retrospective series of 68 patients reported from India reported equivalent toxicities as compared with moderate hypofractionation in this subset of patients.10

Extreme hypofractionation (SBRT) for a total duration of 7 to 10 days, would offer an opportunity to optimise the therapeutic ratio for the treatment of these tumours along with significantly decreasing the overall treatment time which in turn would lead to significantly better quality of life during treatment, early recommencement to daily activities while reducing the financial burden for these patients. We therefore initiated a randomised phase III trial to establish the non-inferiority of SBRT in high-risk and/or node-positive prostate cancer (NCT03561961).

METHODS/DESIGN

Trial design

This is an ongoing, prospective, multicentre, two arm randomised control trial with a non-inferiority design led from a tertiary care cancer centre in India for high-risk node-negative and node-positive prostate cancer patients. Randomisation will be stratified by randomisation method in a 1:1 ratio.

1. Standard arm/moderate hypofractionation: Treatment duration, 5 weeks.
2. Test arm/extreme hypofractionation: Treatment duration, 7 to 10 days.

Stratification will be done for the following parameters:

1. Nodal status: N0 vs N+.
2. 1. luteinizing hormone-releasing hormone (LHRRH) agonist/antagonists versus bilateral orchiectomy.

3. Centre.

The inclusion criteria for the trial will include patients who are older than 18 years with histologically proven adenocarcinoma prostate localised to prostate and pelvic nodes with high-risk/very high-risk disease as per National Cancer Control Network risk stratification (clinical stage T3a or Gleason score 8/ Gleason grade group 4 or Gleason score 9 to 10/Gleason grade group 5, prostate-specific antigen (PSA) >20ng/mL or very high-risk prostate cancer, that is, T3b/T4 or primary Gleason pattern 5/Gleason grade group 5 or >4 cores, Gleason score 8 to 10/Gleason grade group 4 or 5). All patients will be staged with a baseline prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT. In addition, the patients should be fit to receive long-term androgen deprivation therapy in the form of either orchiectomy/hormonal therapy (2 years) and have a baseline Karnofsky Performance Scale of more than equal to 70 (online supplementary appendix 1). The exclusion criteria for the trial includes a distant metastatic disease, a life expectancy of less than 2 years, patient’s with previous history of pelvic radiotherapy (RT), patients with severe urinary symptoms (International Prostate Symptom Score (IPSS) >15) despite being on hormone therapy for 6 months, patients with obstructive urinary symptoms like stricture, patients with contraindication to EBRT like pelvic inflammatory disease and patients with uncontrolled comorbidities (table 1).

Patient and public involvement

Patient/public were not involved in the research methodology of this ongoing study. All patients were given an informed consent form. Only after willingly consenting and understanding all the aspects of participation in the trial, patients were randomised to either of the two arms.

Baseline evaluation and radiotherapy details

The baseline evaluation would include standard workup for a locally advanced carcinoma prostate, that is, transrectal ultrasonography-guided 12 core biopsy and baseline serum PSA level. PSMA PET/CT will be used at baseline to stage all patients. Nodal involvement by disease will be defined as maximum standardised uptake value ≥3.0 irrespective of the size but based on morphological characteristics like shape, heterogeneity and perinodal stranding as determined by expert in uroradiology (PP) and nuclear imaging (VR, AA).

The duration of neoadjuvant androgen deprivation therapy (ADT) ranges from 8 to 12 weeks for node-negative patients and 6 months for node-positive patients. Preferably, all patients will have baseline documentation of quality of life (using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and PR25 questionnaire) and IPSS score at baseline as well as before starting EBRT.

In the standard arm, patients who are randomised to receive moderately hypofractionated RT will receive a total dose of 68 Gy in 25 fractions to the primary
Table 1  Inclusion and exclusion criteria

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| 1. Age: above 18 years | 1. Evidence of distant metastasis at any time since presentation |
| 2. Participants must be histologically proven, adenocarcinoma prostate | 2. Localised to the prostate or pelvic lymph nodes |
| 3. High-risk prostate cancer as per NCCN definition | 3. Previous RT to prostate or prostatectomy |
| 4. PSMA/PET CT for all patients at baseline for staging | 4. Severe urinary symptoms or with severe IPSS score (>15) |
| 5. Ability to receive long-term hormone therapy (2 years)/orchiectomy | 5. Despite being on hormonal therapy for 6 months which in the opinion of the physician precludes RT |
| 6. KPS >70 | 6. Any contraindication to radiotherapy like inflammatory bowel disease |
| 7. No prior history of therapeutic irradiation to pelvis | 7. Uncontrolled comorbidities including, but not limited to diabetes or hypertension |
| 8. Patient willing and reliable for follow-up | 8. Unable to follow-up or poor logistic or social support |
| 9. Signed study specific consent form | **IPSS**, International Prostate Symptom Score; **KPS**, Karnofsky Performance Scale; **NCCN**, National Cancer Control Network; **PET**, positron emission tomography; **PSMA**, prostate-specific membrane antigen; **RT**, radiotherapy.

Table 2  Dose constraints with moderate hypofractionation in arm 1 (standard arm)

| Organ | EQD2 \(\alpha/\beta \) 3 | V30 (25.2 Gy) | V40 (36.8 Gy) | V50 (50 Gy) | V60 (64.8 Gy) | V65 (72.8 Gy) |
|-------|-----------------|----------------|----------------|----------------|----------------|----------------|
| Bladder | N+ | <60% | <40% | <25% | <15% | <3% |
| | N- | <25% | <20% | <14% | <10% | <3% |
| Rectum | N+ | <75% | <50% | <25% | <15% | <5% |
| | N- | <45% | <30% | <20% | <15% | <5% |
| Bowel (cc) | | | | | 80 cc |

EQD2, Equivalent dose at 2Gy per fraction.

over 5 weeks, with treatment being delivered daily. Patients with node-positive disease will receive a dose of 50 Gy in 25 fractions to the pelvis. Response assessment PSMA PET/CT will be done for all patients with pelvic nodal disease to ascertain the response to ADT based on morphology of the residual node and metabolic uptake as defined by the uroradiologist/nuclear medicine specialist. Patients with persistent residual nodal disease will be considered for nodal boost. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 60 to 66 Gy in 25 fractions as a simultaneous integrated boost. An option of equivalent biological dose using 60 to 62.5 Gy in 20 fractions may be allowed for multicentric accrual in the future. In the test arm of study, patients who are scheduled to receive extreme hypofractionated RT (SBRT) will receive a course of five fractions of radiation; each fraction size will be 7.25 Gy. The total dose will be 36.25 Gy. Patients with node-positive disease will receive a dose of 25 Gy in five fractions to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 30 to 35 Gy in five fractions as a simultaneous integrated boost. The five treatments will be scheduled to be delivered alternate day over approximately 7 to 10 days. An option of equivalent biological dose using...
Table 4 Phase 3 trials of SBRT in prostate cancer

| Trial ID            | Study/group                  | Phase 3 trials of SBRT in prostate cancer | Hypofractionated RT in prostate cancer | HYPO-RT-PC | Patriot | Prime       |
|---------------------|------------------------------|------------------------------------------|----------------------------------------|------------|---------|-------------|
| NRG-GU 005          | NRG Oncology                 | Pace A and Pace B\(^{16}\)                | Hypofractionated RT in prostate cancer | HYPO-RT-PC | Patriot | Prime       |
| NCT 03367702        | Royal Marsden NHS Foundation Trust | SBRT (36.25 Gy in five fractions over 12 days) versus moderate hypofractionation (70 Gy in 28 fractions over less than 32 business days.) | SBRT (36.25 Gy in five fractions) every other day over 9 days versus SBRT (36.25 Gy in five fractions) once a week over 28 days | SBRT (42.7 Gy in seven fractions alternate day over 2.5 weeks) versus conventional fractionation (78 Gy in 39 fractions over 8 weeks) | SBRT (40 Gy in five fractions) every other day over 11 days versus SBRT (40 Gy in five fractions) once a week over 29 days | SBRT: 36.25 Gy in 5 fractions over 7–10 days; (node-positive disease - 25 Gy in five fractions) versus moderate hypofractionation: 68 Gy in 25 fractions over 5 weeks; (node-positive disease – 50 Gy in 25 fractions) |
| NCT 01584258        | Geneva, Switzerland           |                                         |                                        |            |         |             |
| NCT 01764646        | Scandinavia                  |                                         |                                        |            |         |             |
| ISRCTN45905321      | Canada                       |                                         |                                        |            |         |             |
| NCT01423474         | Tata Memorial Hospital, India |                                         |                                        |            |         |             |
| NCT03561961         |                              |                                         |                                        |            |         |             |
| Target accrual      | 606                           | 1716                                     | 170                                    | 1200       | 152     | 434         |
| Interventions       | SBRT (36.25 Gy in five fractions over 12 days) versus moderate hypofractionation (70 Gy in 28 fractions over less than 32 business days.) | Pace A: SBRT (36.25 Gy in five fractions) versus radical prostatectomy | Pace B: SBRT (36.25 Gy in five fractions) versus conventional fractionation (78 Gy in 39 fractions) | SBRT (42.7 Gy in seven fractions alternate day over 2.5 weeks) versus conventional fractionation (78 Gy in 39 fractions over 8 weeks) | SBRT (40 Gy in five fractions) every other day over 11 days versus SBRT (40 Gy in five fractions) once a week over 29 days | SBRT: 36.25 Gy in 5 fractions over 7–10 days; (node-positive disease - 25 Gy in five fractions) versus moderate hypofractionation: 68 Gy in 25 fractions over 5 weeks; (node-positive disease – 50 Gy in 25 fractions) |
| Primary end point   | Composite end point of DFS and EPIC-26 urinary and bowel toxicity at 2 years | Pace A: QOL and EPIC score at 2 years | Acute and late urinary, rectal and sexual toxicity at 5 years (CTCAE 3.0) | Freedom from failure (PSA or any clinical), measured 5 years after the end of treatment | EPIC measured bowel related QOL | Biochemical failure free survival at 4 years |
| Estimated accrual completion | December 2025 | September 2021 | Accrual completed | Accrual completed | October 2020 | March 2024 |

AJCC, American Joint Committee on Cancer; CTCAE, Common Terminology Criteria for Adverse Events; DFS, Disease Free Survival; EPIC, Expanded Prostate Cancer Index Composite; GU, genitourinary; NCCN, National Cancer Control Network; NHS, National Health Service; PSA, prostate-specific antigen; QOL, quality of life; RT, radiotherapy; SBRT, stereotactic body radiation therapy; TNM, Tumor Node Metastasis.
Table 5  Published series of SBRT in high-risk prostate cancer

| Author, year, origin | No. of high-risk patients | HR definition | Dose | Median FU (y) | ADT/duration | Acute GU | Acute GI | Late GU | Late GI | Outcomes |
|----------------------|---------------------------|---------------|------|---------------|--------------|----------|---------|---------|---------|----------|
| Kang 2017, Korea \(^{17}\) | 52 | D'Amico | 7–7.25 Gy x 5, | 7 | 55% patients/NS | NS | NS | G2 - 5.1%, G3 - 3% | G2 - 7.1% | 8-y bDFS: 61.3% |
| King 2013, USA \(^{18}\) | 125 | D'Amico | 7–8 Gy x 5 | 3 | 38% high risk patients/4 months | NS | NS | NS | NS | 5-y bDFS: 81% |
| Davis 2015, Radiosurgery Society \(^{19}\) | 33 | NCCN 2015 | 7–9.5 Gy x 4–5 | 1.6 | 15 high risk patients received ADT/NS | NS | NS | G2 - 8% | G2 - 2% | 2-y bDFS: 90% but with PSA >20 ng/mL: 62.5% |
| Ricco 2016, USA \(^{20}\) | 32 | NCCN 2015 | 7–7.5 Gy x 5 | 4.1 | 27% of all SBRT patients/NS | NS | NS | No G3 GU/GI toxicity | 6-y bDFS for SBRT: 92%. 4-y bDFS for HR and VHR: 95% and 72% |
| Katz 2016, USA \(^{21}\) | 38 | NCCN 1.2016 | 7–7.25 Gy x 5 | 7 | Yes/NS | G2 -<5% | G2 -<5% | G2 - 9% | G2 - 4%; G3 - 1.7% | 8-y bDFS: 65% for HR. Favoured unfavourable intermediate 7-y bDFS -93% and 68% |
| Koskela 2017, Finland \(^{22}\) | 111 | D'Amico | 7–7.25 Gy x 5 | 2 | 88.3% high risk/48% of high risk patients ADT >24 months | No acute G3 toxicity | Intermediate GU % GI - 1.8%–0.9% | 23-mo bDFS: 92.8% |
| V Murthy 2018, India \(^{10}\) | 68 | NCCN 37 (54%) patients were N1 | 7–7.25 Gy x 5 | 1.5 | Median duration - 15 months | G2 – 12%; G2 – 4%; G2 – 4% | G2 – 4%; G2 – 4% | 18-mo bDFS: 94% |

ADT, androgen deprivation therapy; bDFS, biochemical disease free survival; GI, gastrointestinal; GU, genitourinary; HR, high risk; mo, months; NCCN, National Cancer Control Network; NS, not specified; PSA, prostate-specific antigen; SBRT, stereotactic body radiation therapy; VHR, very high risk; y, years.
35 to 36.25 Gy in five weekly fractions may be allowed as per institutional practice for multicentric accrual in the future.

All patients will be treated with intensity-modulated radiation therapy or related techniques (helical tomotherapy/volumetric modulated arc therapy) with daily image guidance in the form of kilovoltage-cone beam CT (KV-CBCT)/megavoltage CT. No intraprostatic fiducials will be used for image-guided radiotherapy (IGRT). The contouring of gross tumour volume nodes, clinical target volume (CTV) primary and organs at risk will be done according to standard ESTRO ACROP guidelines. CT nodes will be contoured by giving a radial margin of 5 to 7 mm around the common iliac, external iliac, internal iliac, presacral and the obturator vessels and editing from muscles and bones. The cranial extent of CTV nodes will be at the level of L5–S1 vertebra and the caudal extent will be at the level obturator nodes. For patients without seminal vesicle involvement only 1.5 cm of the base of seminal vesicles will be included in CTV primary whereas the entire seminal vesicle will be included in the CTV primary in patients with radiological involvement of seminal vesicle. A planning target volume (PTV) margins of 5 mm will be given around the entire CTV primary (including seminal vesicles) and CTV nodes to delineate PTV primary and PTV nodes, respectively. The dose volume constraints for the target volume will include a CTV D98 of 98% (both primary and nodes) and a PTV D98 of 95% (both primary and nodes). These contouring and dose constraints are in accordance with the retrospective series of SBRT for high-risk and/or node-positive prostate cancer published from the same institute.

The dose volume constraints for organs at risk is given in tables 2 and 3.

### Assessment/follow-up

Patients will continue (LHRH agonist/antagonist) during radiotherapy. All patients will be monitored during radiotherapy and at every follow-up for acute/late toxicities using Radiation Therapy Oncology Group (RTOG) and Common Terminology Criteria for Adverse Events (CTCAE) 4.03 toxicity grading scales (online supplementary appendix 2–4). In addition, out-of-pocket expenditure (online supplementary appendix 5) of the patient and caregiver for food, travel, stay and for management of treatment related side effects will be captured using a structured record form along with quality of life score, IPSS score and urinary function. All patients will be followed up after 4 to 6 weeks of completion of radiotherapy and then at 3 to 6 monthly intervals until 2 years and 6 monthly intervals thereafter. Patients will continue LHRH agonists/antagonist after completion of radiotherapy to complete a total duration of 2 years. Clinical evaluation of the disease will be done at each follow-up visit with a serum PSA and clinical examination. Any other investigation will be done at the physician’s discretion.

### Statistics

The primary end point of this study will be 4-year biochemical failure free survival (BFFS) which will be defined as the time (in months) from the date of randomisation to the date of biochemical failure as per Phoenix Criteria (a rise in PSA level of more than 2 ng/mL above the nadir). This is a non-inferiority trial and the non-inferiority margin between the standard and the test arms is 9% (delta). To detect this delta difference in the primary end point of a 4-year BFFS (80% in standard arm and 71% in the test arm; HR 1.53), with a power of 80% and a one-sided 5% alpha value, total of 135 events are required, with a minimum number of 422 patients. The assumption of 80% BFFS in the standard arm was based on the results of similar studies of high-risk node-negative cancer studies (STAMPEDE, James ND et al JAMA oncology 2016 and PRO 7, J Clin Oncol 2015) and our own data (unpublished) which showed a 5-year BFFS of about 85%. As this study is recruiting high-risk and node-positive patients also, the upper limit of 80% was chosen. Non-inferiority of extreme hypofractionation with SBRT (test arm) versus moderate hypofractionated RT (standard arm) will be concluded if the upper limit of the estimated 95% one-sided CI of the HR obtained lies entirely below 1.53. If the upper limit of the 95% one-sided CI is 1.53 or higher, we do not reject the null hypothesis of inferiority. The trial will accrue patients over a period of 6 years and all patients will be followed until the end of study. Considering an attrition rate of around 5%, the trial would continue until the planned sample size (n=434). We do not reject the null hypothesis of inferiority. The primary efficacy analysis will be on both intention-to-treat and per-protocol basis.

The secondary end points for the study will be evaluation of the acute and late toxicities (according to RTOG and CTCAE criterion), ascertaining the overall survival and prostate cancer specific survival for these patients, estimation of out-of-pocket expenditure involved in patients receiving the two treatment schedules and assessment of pre-treatment and post-treatment quality of life of these patients. For this study, overall survival and prostate cancer specific survival will be defined as time in months between date of randomisation and date of death due to any cause or date of death due to prostate cancer, respectively.

A planned interim analyses will be done on accrual of 25% (108 patients in both arms combined) patients completing 2 years of follow-up. At the interim analysis, the p value from the X² or Fisher’s exact test assessing treatment efficacy with respect to grade III or higher combined gastrointestinal (GI) and genitourinary (GU) RTOG toxicity will be compared in the two arms at one-sided alpha of 2.5% and a power of 80%. If the computed p value is less than or equal to 0.025, then accrual to the trial will be discussed with the Data Safety and Monitoring Committee for stopping (if applicable). Otherwise, accrual to the trial or follow-up (as applicable) will continue until the planned sample size (n=134). We expect 80 patients to be accrued per year in the project.
Quality assurance
Radiation therapy quality assurance in the setting of a multi-institutional clinical trial has been shown to have a very important bearing on outcomes. The US National Cancer Institute Work Group on Radiotherapy Quality Assurance has laid down guidelines that help individual trials lay down their quality assurance (QA) protocol (Bekelman et al 2012). The PRIME trial will use these guidelines to formulate a trial specific protocol as outlined below.

Tiered system for radiotherapy trial QA
Tier 1 includes general credentialing which comprises of filling a facility questionnaire outlining machine-specific and patient-specific QA process.

Tier 2 is a trial specific credentialing consists of a dry run process with oncologists and physicists familiarising themselves with the contouring protocol and advanced dosimetry checks with multiple plan generation to meet trial constraints.

Tier 3 is an individualised case review of dosimetry and QA data sheet reviewed every monthly in virtual QA meet.

DISCUSSION
The efficacy of SBRT for prostate cancer is supported by a radiobiological basis as well as phase 1 and phase 2 single arm studies. Several single arm series have established the efficacy and safety of SBRT for low-risk and intermediate-risk prostate cancer. The results of ongoing phase 3 trials comparing extreme hypofractionation to moderate hypofractionation/conventional fractionation are awaited. (table 4). The major concern with SBRT is the impact on acute and late toxicities of the patients. The HYPO-RT-PC trial accrued 1200 intermediate-risk prostate cancer patients (T1c to T3a, PSA <10) with one or two of the following risk factors: T3a or Gleason 7 or PSA >10) and tested conventionally fractionated RT against extreme hypofractionation. Preliminary results show no significant differences in the prevalence of physician reported grade 2+ toxicity at 2 years between the two arms for urinary (3.4% vs 4.6%, p=0.59) and bowel (2.2% vs 3.7%, p=0.02) toxicity.8

The reports for SBRT as monotherapy for high-risk disease are limited as most contemporary series have included very few high-risk prostate cancers (table 5). The dose per fraction given in these series range from 7 to 8 Gy in four to fix fractions given over 7 to 14 days. The toxicities and outcomes are comparable to that expected with moderate hypofractionation schedules with the GI and GU RTOG ≥2 late toxicities ranging from 2% to 14%.

FASTR is a phase 1 feasibility study for SBRT for node-positive disease which delivered a dose of 25 Gy to pelvic nodes and 40 Gy to primary over a period of 5 weeks (once weekly fractionation). Nine out of the 15 patients accrued (60%) developed ≥Gr (grade) 2 GI or GU toxicity at 6 months and 4 (30%) ≥Gr 3 GI or GU toxicity at 6 months. The study was terminated before phase 2 in view of the higher toxicities.14 Another single arm study (SATURN) evaluated a similar protocol with a dose of 25 Gy to pelvic nodes and seminal vesicle, 40 Gy as simultaneous integrated boost to the prostate and 33.25 Gy to the prostate PTV delivered over a period of 5 weeks in five once weekly fractions. The authors reported a Gr 2 GU toxicity of 52% (baseline 30%) and 32% GI toxicity (baseline 3.3%) at 6 months. No grade 3 toxicities were reported. The authors attributed the lesser toxicity of this study as compared with the FASTR protocol to the lesser dose prescription to the prostate PTV (40 vs 33.25 Gy), the lesser PTV margins (5 mm vs 3 mm), smaller CTV volumes and better image guidance in SATURN protocol.9

In the present trial, the dose to primary PTV will be 36.25 Gy in five fractions, which is between those given in FASTR and SATURN trials. The efficacy and safety of such a dosing schedule has already been published as a single arm retrospective series from India with an 18-month biochemical disease free survival of 94% and incidence of ≥Gr 3 late GU and GI toxicity of 3% and 0%, respectively. In addition, the PTV margins are 5 mm which again has been shown to adequate with daily CBCT based IGRT.15

This trial aims to establish a therapeutically efficacious and cost-efficient modality for high-risk, very high-risk and node-positive prostate cancer which is likely to be a big public health problem in low-income/low-middle-income countries in the coming decade. Presently, this is the only trial evaluating and answering such a question in this cohort.

Author affiliations
1Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India
2Department of Radiation Oncology, Tata Medical Centre, Kolkata, India
3Clinical Research Secretariat, Tata Memorial Centre, Mumbai, India
4Division of Uro-Oncology, Tata Memorial Centre, Mumbai, India
5Department of Pathology, Tata Memorial Centre, Mumbai, India
6Department of Radiology, Tata Memorial Centre, Mumbai, India
7Department of Nuclear Imaging and Bio imaging, Tata Memorial Centre, Mumbai, India
8Twitter Abhilash Gavarraju @AbhiG76898224

Contributors Study concept and design: VM, IM; Selection accrual and consenting of patients: VM, IM, AG, SS, RK, TT, AM; Patient examination and clinical evaluation: VM, IM, AG, SS, RK, TT, AM, MB, GP, MP; Radiological evaluation: PP, VR, AA; Pathological evaluation: SM; Statistical Analysis and Interpretation: SK; Data collection and Master File maintenance: SK. All authors have read and approved the manuscript.

Funding This ongoing study is funded by an intramural grant from Tata Memorial Centre, Mumbai (TRAC/0518/000271/001). No industry or pharmaceutical support has been received. The granting bodies are not involved in data collection or analysis.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Signature of the informed consent will be obtained from all patients before inclusion in the study. This ongoing study was approved by Institutional Ethics Committee of Tata Memorial Hospital, Mumbai (TMC IRB Project No: -271/CTRi No: CTRI/2018/05/014054). This study was approved by Institutional Ethics Committee of Tata Medical Center, Kolkata (2018/TMC/134/IRB32). This...
REFERENCES

1 Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. JCO 2010;28:1117–23.
2 Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol 2013;23:331–6.
3 Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Med J Armed Forces India 2014;2:596–605.
4 Hanifah N, Padmanabha V. Demography and disease characteristics of prostate cancer in India. Indian J Urol 2016;32:103.
5 Hebert JT, Ghumare SS, Gupta PC. Stage at diagnosis and relative differences in breast and prostate cancer incidence in India: comparison with the United States. Asian Pac J Cancer Prev 2006;7:547–55.
6 Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 2013;85:89–94.
7 Dearnaley DP, Sydes MR, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012;13:43–54.
8 Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet 2019;394:385–95.
9 Musunuru HB, D’Alimonte L, Davidson M, et al. Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURAN): early toxicity and quality of life. Int J Radiat Oncol Biol Phys 2018;102:1438–47.
10 Murthy V, Gupta M, Mulve G, et al. Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high-risk and node-positive prostate cancer. Clin Oncol 2018;30:442–7.
11 Salemnier C, Vileirs G, De Bari B, et al. ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol 2018;127:49–61.
12 Murthy V, Sinha S, Kannan S, et al. Safety of prostate stereotactic body radiation therapy after transurethral resection of prostate (TURP): a propensity score matched pair analysis. Pract Radiat Oncol 2019;9:347–53.
13 Bekelman JE, Deyo JA, Vikram B, et al. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials—report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys 2012;83:782–90.
14 Bauman G, Ferguson M, Lock M, et al. A phase 1/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2015;92:856–62.
15 Quon HC, Ong A, Cheung P, et al. Once-Weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (patio): a phase 2 randomized trial. Radiat Oncol 2018;127:206–12.
16 Brand DH, Tree AC, Ostler P, et al. Intensity-Modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PAGE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019;20:10.
17 Kang J, Katz AJ. Management of high-risk prostate cancer with 5-treatment stereotactic body radiotherapy: long-term results. JCO 2017;35:94.
18 King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional Consortium of prospective phase II trials. Radiat Oncol 2013;10:217–21.
19 Davis J, Sharma S, Shumway R, et al. Stereotactic body radiotherapy for clinically localized prostate cancer: toxicity and biochemical disease-free outcomes from a multi-institutional patient registry. Cureus 2015;7:e395.
20 Ricco A, Manahan G, Lazzaro R, et al. The comparison of stereotactic body radiation therapy and intensity-modulated radiation therapy for prostate cancer by NCCN risk groups. Front Oncol 2016;6:184.
21 Katz A, Kang J. Stereotactic body radiation therapy for localized prostate cancer: risk stratification for intermediate- and high-risk patients. Int J Radiat Oncol Biol Phys 2016;96:E250.
22 Koskela K, Palmgren J-E, Heikkilä J, et al. Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience. Acta Oncol 2017;56:978–83.